Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab. We aimed to characterize the time course of CD19+ B lymphocytes (CD19+) under treatment with intravenous rituximab in children with neurolog...
Saved in:
Main Authors: | Natalia Riva (Author), Lucas Brstilo (Author), Aymara Sancho-Araiz (Author), Manuel Molina (Author), Andrea Savransky (Author), Georgina Roffé (Author), Marianela Sanz (Author), Silvia Tenembaum (Author), Maria M. Katsicas (Author), Iñaki F. Trocóniz (Author), Paula Schaiquevich (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
by: Aymara Sancho-Araiz, et al.
Published: (2021) -
Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases
by: Natalia Riva, et al.
Published: (2022) -
Neuromyelitis optica associated with systemic autoimmune diseases in children
by: Russo RA, et al.
Published: (2008) -
Rituximab in Autoimmune CNS Disease
by: J Gordon Millichap, et al.
Published: (2014) -
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
by: Amer M. Khojah, et al.
Published: (2019)